Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (monocyte progenitors) | 0.10 |
| chemistry Open Targets | compounds already reach it: cenicriviroc, azd2423, mk-0812 +7 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 29 Parkinson's papers of 6,273 | 0.55 |
| pathways Reactome | 5 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3959
Sealed predictions
- CCR2 in dopamine neurons, braak+0.04 (p 0.924) → +0.40 (p 0.292)receipt 3966
Swarm cases
receipt 3966: CCR2 in dopamine neurons, braak
- power
- full sample +0.18 (p 0.471, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.16 (p 0.538, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.05 (p 0.840, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.33, sign flips 0; without severely affected donors +0.18 (p 0.471, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts